**Congenital Muscular Dystrophy (CMD):** Two $42,406 grants or one $84,812 grant will be awarded depending on the merit, feasibility, and budget justification (please indicate solicited budget level on your LOI).

Purpose: Promote the discovery of underlying disease mechanisms and the preclinical development of potential therapies, as well as the clinical translation of those efforts for Collagen VI Congenital Muscular Dystrophy.

Areas of Interest: Including but not limited to, 1) understanding the cause of disease, 2) understanding tissue-specific phenotypes, 3) unraveling pathways involved in disease, 4) identifying novel drug targets or gene therapies, and 5) testing new strategies to treat disease or any of its incapacitating consequences (e.g. contractures, respiratory function decline). We will also accept applications proposing to create or improve disease models (e.g. animal models, patient-derived cell models), and encourage applications on biomarker discovery or functional outcome measures to assess therapeutic impact in an effort to bring COL6-CMD closer to Clinical Trial Readiness.